Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER-/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?

Pathology oncology research : POR - 1 Oct 2018

Foley Niamh M, Coll J M, Lowery A J, Hynes S O, Kerin M J, Sheehan M, Brodie C, Sweeney K J

Abstract excerpt

Expression of the ER and PR receptors is routinely quantified in breast cancer as a predictive marker of response to hormonal therapy. Accurate determination of ER and PR status is critical to the optimal selection of patients for targeted therapy. The existence of an ER-/PR+ subtype is controversial, with debate centred on whether this represents a true phenotype or a technical artefact on immunohistochemistry...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Artifacts

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Breast Neoplasms

Share to Immunohistochemistry

Share to Phenotype

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Source

Identifiers

PMID: 28891017
DOI: 10.1007/s12253-017-0304-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER-/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?PMID 28891017Read ↗

The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact.Semantic proximity Read ↗

Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.Semantic proximity Read ↗

Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.Semantic proximity Read ↗

Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCRSemantic proximity Read ↗

High incidence of oestrogen receptor negative progesterone receptor positive phenotype in Indian breast cancer: fact or fiction?Semantic proximity Read ↗

Triple-negative breast cancer: a threshold-defined diagnostic category within a biological continuum.Semantic proximity Read ↗

Estrogen receptor expression in human tumors: A tissue microarray study evaluating more than 18,000 tumors from 149 different entitiesSemantic proximity Read ↗

The loss of progesterone receptor predicts more aggressive biological features and worse outcomes in estrogen receptor-positive and HER2-negative inflammatory breast cancerSemantic proximity Read ↗

Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.Semantic proximity Read ↗

Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.Semantic proximity Read ↗

ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer.Semantic proximity Read ↗

Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.